• Global Clinical Research & Health Data Analytics Company
  • The MMS Difference
    • About Us
    • Leadership
    • Certifications
  • Services
    • Regulatory Affairs and Operations
    • Data Management and Biostatistics
    • Regulatory and Medical Writing
    • Drug Safety and Pharmacovigilance
    • Compliance and Transparency
    • Data Sciences
  • Working with MMS
  • News and Media
  • Webinars
  • MMS Blog
  • Careers
  • Contact Us
MMS Holdings
PhUSE: Retrospective vs. Proactive Anonymization of Narratives

PhUSE: Retrospective vs. Proactive Anonymization of Narratives

by Don McLean | Mar 14, 2019 | Blog

PhUSE: Retrospective vs. Proactive Anonymization of Narratives Exerpt from whitepaper originally published by PhUSE on March 14, 2019 by project co-leads – Rashmi Dodia, MS, RAC and Gregory Campbell, BS Executive Summary Ever since policy 0070 was first introduced in...
Safety Writing, REMS, and Regulatory Requirements: A Conversation with Jeffrey Wiese

Safety Writing, REMS, and Regulatory Requirements: A Conversation with Jeffrey Wiese

by Don McLean | Feb 7, 2019 | Blog

Safety Writing, REMS, and Regulatory Requirements: A Conversation with Jeffrey Wiese by Staff writer In this Expert Insights interview, we sit down with Jeffrey Wiese, Senior Safety Writer at MMS – to discuss safety writing in the pharmaceutical industry,...

Recent Posts

  • Modernizing the Functional Service Provider (FSP) Relationship: Innovations to bring value beyond “Global and Scalable”
  • EY Announces Dr. Uma Sharma of MMS Holdings as an Entrepreneur Of The Year® 2020 Michigan and Northwest Ohio Award Finalist
  • MichBio Invites MMS Founder and Chief Scientific Officer Dr. Uma Sharma to Join Board of Directors
  • How Zero Contact GXP Audits Ensure Compliance While Protecting Auditors and Auditees during the Global Pandemic
  • FDA Orphan Drug Designation Applications Whitepaper

Tags

ALZ awareness Alzheimers biosimilars biostatistics Clinical Development clinical research clinical study reports clinical trials clinical trial transparency Community Compliance COVID-19 CRO data management data privacy data science drug development EMA ENDALZ FDA Flint GDPR GXP auditing Health Analytics Collective Health Canada Lay summaries leadership medical writing NDA submission opioids pharma pharmacovigilance PhUSE Policy 0070 quality control rare disease real world data regulatory operations REMS resourcing statistical programming suicidality transparency trial regulation Volunteering